This is the authors' abstract. We don't add key points for this paper.
A new family of iron(II) aryloxide [Fe(OAr)(2)(py)(x)] precursors was synthesized from the alcoholysis of iron(II) mesityl [Fe(Mes)(2)] in pyridine (py) using a series of sterically varied 2-alkyl phenols (alkyl = methyl (H-oMP), isopropyl (H-oPP), tert-butyl (H-oBP)) and 2,6-dialkyl phenols (alkyl = methyl (H-DMP), isopropyl (H-DIP), tert-butyl (H-DBP), phenyl (H-DPhP)). All of the products were found to be mononuclear and structurally characterized as [Fe(OAr)(2)(py)(x)] (x = 3 OAr = oMP (1), oPP (2), oBP (3), DMP (4), DIP (5); x = 2 OAr = DBP (6), DPhP (7)). The use of tris-tert-butoxysilanol (OSi(OBu(t))(3) = TOBS) led to isolation of [Fe(TOBS)(2)(py)(2)] (8). The new Fe(OAr)(2)(py)(x) (1-6) were found, under solvothermal conditions, to produce nanodots identified by PXRD as the γ-maghemite phase. The model precursor 3 and the nanoparticles 6n were evaluated using electrochemical methods. Cyclic voltammetry for 3 revealed multiple irreversible oxidation peaks, which have been tentatively attributed to the loss of alkoxide ligand coupled with the deposition of a solid Fe-containing coating on the electrode. This coating was stable out to the voltage limits for the acetonitrile solvent.
No takes yet. Share an insight, caveat, or question.
Boyle et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: